Skip to main content
Premium Trial:

Request an Annual Quote

Tempus Submits PMA Application for Tumor Profiling Assay to FDA

NEW YORK – Tempus said on Tuesday that it has submitted a premarket approval application for its next-generation sequencing-based xT-Onco tumor profiling assay to the US Food and Drug Administration.

The firm has submitted companion diagnostic claims, tumor profiling claims, and microsatellite instability status, using DNA isolated from formalin-fixed paraffin-embedded tumor tissue specimens, and matched normal specimens. Tempus will perform the assay at its lab in Chicago.

"Oncologists throughout the country leverage Tempus' sequencing assays to inform data-driven treatment decisions and deliver personalized patient care," Lauren Silvis, Tempus senior VP of regulatory affairs, said in a statement. "This regulatory milestone demonstrates our commitment to expanding the promise of precision medicine in oncology to more patients and providers."

The xT platform uses NGS to detect somatic single nucleotide variants, insertions, and deletions across 648 genes, as well as gene fusions using whole-transcriptome sequencing, and integrates the molecular data with structured patient clinical data.

Tempus received CE marking for the assay in November 2020.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.